心肌细胞KLF5促进神经酰胺从头合成并参与缺血性心肌病离心性重构
该研究在缺血性心衰患者和小鼠MI模型中观察到心肌细胞KLF5表达升高,KLF5通过上调SPTLC1/SPTLC2促进神经酰胺从头合成;遗传或药物抑制KLF5可减少神经酰胺蓄积、减轻离心性重构并提高射血分数,提示KLF5是缺血性心衰的潜在治疗靶点。
要点
- 缺血性心衰患者和小鼠MI后心肌KLF5表达升高。
- 抑制KLF5可减少心肌神经酰胺蓄积并改善MI后心功能。
- KLF5通过上调SPTLC1/SPTLC2促进神经酰胺从头合成。
核心结论
- KLF5在人类和小鼠缺血性心衰发展过程中被诱导并刺激神经酰胺生物合成。
- 在小鼠MI中遗传或药物抑制KLF5可防止神经酰胺蓄积、减轻离心性重构并提高射血分数。
- KLF5成为治疗缺血性心衰的新治疗靶点。
研究设计与样本
- 采用实时PCR和Western blot检测MI小鼠模型及缺血性心衰患者心脏组织中KLF5表达变化。
- 使用2D超声心动图评估药物KLF5抑制剂ML264及心肌细胞特异性KLF5缺失小鼠(αMHC-KLF5-/-)MI后的效果。
- 采用液相色谱-串联质谱及Western blot和实时PCR分析神经酰胺代谢相关基因,鉴定KLF5在MI后脂质代谢和神经酰胺蓄积中的作用。
- 评估心肌细胞特异性KLF5过表达(αMHC-rtTA-KLF5)对心脏功能和神经酰胺代谢的影响,并用myriocin抑制神经酰胺生物合成以挽救表型。
主要发现
- KLF5 mRNA和蛋白水平在人类缺血性心衰样本及啮齿类动物永久性左冠状动脉结扎后24小时、2周和4周模型中较高。
- αMHC-KLF5-/-小鼠和ML264处理小鼠MI后射血分数较高、心室容积和心脏重量较低。
- 脂质组学分析显示αMHC-KLF5-/-小鼠MI后心肌神经酰胺水平低于同窝对照MI小鼠,而αMHC-KLF5-/-小鼠基础神经酰胺含量与对照小鼠无差异。
- KLF5缺失抑制调节神经酰胺从头生物合成的SPTLC1和SPTLC2表达。
- 心肌SPTLC1和SPTLC2水平在心衰患者中升高;αMHC-rtTA-KLF5小鼠SPTLC1和SPTLC2表达增加、心肌神经酰胺水平升高,KLF5诱导后2周开始出现收缩功能障碍。
临床怎么用
- KLF5抑制或可作为缺血性心衰中减少神经酰胺蓄积、减轻离心性重构并改善射血分数的潜在策略。
- 心肌神经酰胺水平及SPTLC1/SPTLC2表达可能作为缺血性心衰中KLF5通路激活的监测指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We previously showed that cardiomyocyte Krϋppel-like factor (KLF) 5 regulates cardiac fatty acid oxidation. As heart failure has been associated with altered fatty acid oxidation, we investigated the role of cardiomyocyte KLF5 in lipid metabolism and pathophysiology of ischemic heart failure. METHODS: Using real-time polymerase chain reaction and Western blot, we investigated the KLF5 expression changes in a myocardial infarction (MI) mouse model and heart tissue from patients with ischemic heart failure. Using 2D echocardiography, we evaluated the effect of KLF5 inhibition after MI using pharmacological KLF5 inhibitor ML264 and mice with cardiomyocyte-specific KLF5 deletion (αMHC [α-myosin heavy chain]-KLF5-/-). We identified the involvement of KLF5 in regulating lipid metabolism and ceramide accumulation after MI using liquid chromatography-tandem mass spectrometry, and Western blot and real-time polymerase chain reaction analysis of ceramide metabolism-related genes. We lastly evaluated the effect of cardiomyocyte-specific KLF5 overexpression (αMHC-rtTA [reverse tetracycline-controlled transactivator]-KLF5) on cardiac function and ceramide metabolism, and rescued the phenotype using myriocin to inhibit ceramide biosynthesis. RESULTS: KLF5 mRNA and protein levels were higher in human ischemic heart failure samples and in rodent models at 24 hours, 2 weeks, and 4 weeks post-permanent left coronary artery ligation. αMHC-KLF5-/- mice and mice treated with ML264 had higher ejection fraction and lower ventricular volume and heart weight after MI. Lipidomic analysis showed that αMHC-KLF5-/- mice with MI had lower myocardial ceramide levels compared with littermate control mice with MI, although basal ceramide content of αMHC-KLF5-/- mice was not different in control mice. KLF5 ablation suppressed the expression of SPTLC1 and SPTLC2 (serine palmitoyltransferase [SPT] long-chain base subunit ()1 2, respectively), which regulate de novo ceramide biosynthesis. We confirmed our previous findings that myocardial SPTLC1 and SPTLC2 levels are increased in heart failure patients. Consistently, αMHC-rtTA-KLF5 mice showed increased SPTLC1 and SPTLC2 expression, higher myocardial ceramide levels, and systolic dysfunction beginning 2 weeks after KLF5 induction. Treatment of αMHC-rtTA-KLF5 mice with myriocin that inhibits SPT, suppressed myocardial ceramide levels and alleviated systolic dysfunction. CONCLUSIONS: KLF5 is induced during the development of ischemic heart failure in humans and mice and stimulates ceramide biosynthesis. Genetic or pharmacological inhibition of KLF5 in mice with MI prevents ceramide accumulation, alleviates eccentric remodeling, and increases ejection fraction. Thus, KLF5 emerges as a novel therapeutic target for the treatment of ischemic heart failure.
引用
- Hoffman M, Palioura D, Kyriazis ID, et al. Cardiomyocyte Krüppel-Like Factor 5 Promotes De Novo Ceramide Biosynthesis and Contributes to Eccentric Remodeling in Ischemic Cardiomyopathy. Circulation. 2021. PMID: 33430631. doi:10.1161/CIRCULATIONAHA.120.047420
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。